More about

Olaparib

News
June 03, 2023
2 min read
Save

Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer

Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.

News
June 01, 2023
1 min read
Save

FDA approves Lynparza regimen for certain men with BRCA-positive prostate cancer

FDA approves Lynparza regimen for certain men with <i>BRCA</i>-positive prostate cancer

The FDA approved olaparib in combination with abiraterone acetate and prednisone or prednisolone for men with suspected deleterious or deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

News
May 27, 2023
1 min read
Save

Durvalumab regimens extend PFS in advanced endometrial cancer

Durvalumab regimens extend PFS in advanced endometrial cancer

The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.

News
April 28, 2023
3 min read
Save

FDA committee favors restricting prostate cancer regimen to BRCA-positive subgroup

FDA committee favors restricting prostate cancer regimen to <i>BRCA</i>-positive subgroup

An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.

News
April 19, 2023
3 min read
Save

Combination therapy shows preliminary antitumor activity in pediatric neuroblastoma

Combination therapy shows preliminary antitumor activity in pediatric neuroblastoma

The combination of olaparib and the investigational ATR inhibitor ceralasertib induced antitumor responses in children and adolescents with DNA repair-deficient tumors, according to phase 1 results of the AcSé-ESMART trial.

News
March 27, 2023
2 min read
Save

Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer

Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

News
February 01, 2023
2 min read
Save

Talazoparib may benefit patients with PALB2-mutated breast cancer

Talazoparib may benefit patients with <i>PALB2</i>-mutated breast cancer

Talazoparib appeared effective among certain patients with advanced, PALB2-mutated breast cancer, according to study results published in Nature Cancer.

News
September 09, 2022
3 min read
Save

Olaparib regimen extends survival for certain women with advanced ovarian cancer

Olaparib regimen extends survival for certain women with advanced ovarian cancer

Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.

News
August 16, 2022
1 min read
Save

FDA grants priority review to Lynparza regimen for advanced prostate cancer

FDA grants priority review to Lynparza regimen for advanced prostate cancer

The FDA granted priority review to olaparib as part of combination therapy treatment of metastatic castration-resistant prostate cancer.

News
March 23, 2022
2 min read
Save

Adjuvant olaparib prolongs survival for certain patients with early breast cancer

Adjuvant olaparib prolongs survival for certain patients with early breast cancer

Adjuvant olaparib significantly extended OS among patients with HER2-negative high-risk early-stage breast cancer and germline BRCA1/BRCA2 mutations, according to results of the randomized phase 3 OlympiA study.

View more